Tech Company Financing Transactions
Tarsa Therapeutics Funding Round
Tarsa Therapeutics, based in Philadelphia, secured $549.9 thousand from private investors.
Transaction Overview
Company Name
Announced On
7/26/2017
Transaction Type
Debt
Amount
$549,858
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 3 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
8 Penn Center 1628 John F. Kennedy Blvd. 1400
Philadelphia, PA 19103
USA
Philadelphia, PA 19103
USA
Phone
Website
Email Address
Overview
Tarsa Therapeutics is developing an oral formulation of calcitonin, a peptide hormone for the treatment of osteoporosis that slows the rate of bone destruction.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Brand
Chief Medical Officer
David Krause
Chief Scientific Officer
James Gilligan
VP - Regulatory Affairs
Nicholas LaBella
Browse more venture capital transactions:
Prev: 7/26/2017: Prospera venture capital transaction
Next: 7/26/2017: Fulcrum Therapeutics venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. All VC database entries on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs